Faire une nouvelle recherche
Make a new search
Lancer la recherche

Titre du document / Document title

Cost-Effectiveness Analysis on Pioglitazone Add-On Therapy to Patients Failing Insulin = Klinischer und ökonomischer Nutzen der Kombinationstherapie von Insulin und Pioglitazon unter deutschen Praxisbedingungen [nl]Gesundheitsökonomische Modellierung von klinischen und ökonomischen Langzeiteffekten bei Patienten mit Typ-2-Diabetes Mellitus

Auteur(s) / Author(s)

Gschwend M. H. (1) ; Beaudet A. ; Heddaeus H. ; Lange M. ; Kremer-König J. ; Landers B. ; Schlaeger C. ; Sandtmann R. ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) IMS Health, Basel, Schweiz

Résumé / Abstract

AIM: The aim of this study was to model the long-term effects of adding pioglitazone to insulin in type 2 diabetes mellitus patients in a German real-world setting. METHODS: Analyses were conducted using the Core Diabetes Model, with patients’ baseline characteristics, risk factors and complication rates taken from a non-interventional study recently performed in Germany. The healthcare provider’s perspective was adopted over a 35 years time horizon using a 3.0 % discount rate for cost and clinical benefits. RESULTS: Patients with pioglitazone plus insulin treatment were projected to have a quality-adjusted life expectancy of 6.32 ± 0.12 QALYs versus 6.04 ± 0.11 QALYs for insulin, a decreased onset of all diabetes-related complications and a generally lower cumulative incidence of diabetes-related complications. Higher drug acquisition costs of the combination treatment could partly be offset by decreases in complications. The ICER of pioglitazone and insulin versus insulin alone was 9,984 € per QALY gained. In a subgroup of high responders (patients in which insulin use was decreased by more than 20 % in combination with pioglitazone), pioglitazone as add-on to insulin treatment showed to be cost-saving. CONCLUSION: The addition of pioglitazone to insulin treatment was projected to be highly cost-effective in the German setting when compared to insulin from a healthcare payer perspective.

Revue / Journal Title

Gesundheitsökonomie & Qualitätsmanagement    ISSN  1439-4049 

Source / Source

2011, vol. 16, no06, pp. 355-362 [8 page(s) (article)]

Langue / Language


Editeur / Publisher

Thieme, Stuttgart, ALLEMAGNE  (2001) (Revue)

Mots-clés d'auteur / Author Keywords

diabetes mellitus type 2


cost-effectiveness analysis








Localisation / Location


© Georg Thieme Verlag KG Stuttgart · New York
Nº notice refdoc (ud4) : 25226501

Faire une nouvelle recherche
Make a new search
Lancer la recherche